Lantheus Holdings (LNTH) Consolidated Net Income (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Consolidated Net Income came in at $118.4 million in Q1 2026, up 62.34% year-on-year from $72.9 million in Q1 2025, and down 16.68% on a QoQ basis from $142.1 million in Q4 2025.
Lantheus Holdings (LNTH) Consolidated Net Income (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Consolidated Net Income data on file, last reported at $118.4 million in Q1 2026.
- On a quarterly basis, Consolidated Net Income rose 62.34% year-over-year to $118.4 million in Q1 2026; TTM through Mar 2026 was $367.1 million, a 566.01% increase from a year earlier, with the FY2025 full-year figure at $321.6 million, up 1657.63% from the prior year.
- Consolidated Net Income for Q1 2026 stood at $118.4 million, down from $142.1 million in the prior quarter.
- Over the last five years, Consolidated Net Income for LNTH reached as high as $142.1 million in Q4 2025 and fell as low as -$344.9 million in Q4 2024.
- Historically, Consolidated Net Income has averaged $45.4 million across 5 years, with a median of $72.9 million in 2025.
- On a YoY basis, Consolidated Net Income climbed as much as 4769.26% in 2024 and fell as far as 440.24% in 2024.
- Year by year, Consolidated Net Income stood at -$119.2 million in 2022, then surged by 185.05% to $101.4 million in 2023, then tumbled by 440.24% to -$344.9 million in 2024, then soared by 141.21% to $142.1 million in 2025, then declined by 16.68% to $118.4 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were $118.4 million in Q1 2026, $142.1 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 118.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 142.12 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -344.88 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 101.36 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |
| Jun 30, 2021 | -26.66 Mn |